case | 31 May 2023
Setterwalls has advised Alligator Bioscience in connection with rights issue of approximately SEK 181 million
![Responsive image](https://setterwalls.se/wp-content/uploads/2021/08/handshake_3-1200x500.jpg)
Setterwalls has advised Alligator Bioscience AB (“Alligator”), listed on Nasdaq Stockholm, in connection with a rights issue of units of approximately SEK 181 million.
Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s shares are listed on Nasdaq Stockholm, and the company is headquartered in Lund, Sweden.
Contact:
Practice areas: